BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 19257896)

  • 1. Engineering the vaccinia virus L1 protein for increased neutralizing antibody response after DNA immunization.
    Shinoda K; Wyatt LS; Irvine KR; Moss B
    Virol J; 2009 Mar; 6():28. PubMed ID: 19257896
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting the vaccinia virus L1 protein to the cell surface enhances production of neutralizing antibodies.
    Golden JW; Josleyn MD; Hooper JW
    Vaccine; 2008 Jun; 26(27-28):3507-15. PubMed ID: 18485547
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Polyclonal antibody cocktails generated using DNA vaccine technology protect in murine models of orthopoxvirus disease.
    Golden JW; Zaitseva M; Kapnick S; Fisher RW; Mikolajczyk MG; Ballantyne J; Golding H; Hooper JW
    Virol J; 2011 Sep; 8():441. PubMed ID: 21933385
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Potent neutralization of vaccinia virus by divergent murine antibodies targeting a common site of vulnerability in L1 protein.
    Kaever T; Meng X; Matho MH; Schlossman A; Li S; Sela-Culang I; Ofran Y; Buller M; Crump RW; Parker S; Frazier A; Crotty S; Zajonc DM; Peters B; Xiang Y
    J Virol; 2014 Oct; 88(19):11339-55. PubMed ID: 25031354
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antibodies to the A27 protein of vaccinia virus neutralize and protect against infection but represent a minor component of Dryvax vaccine--induced immunity.
    He Y; Manischewitz J; Meseda CA; Merchlinsky M; Vassell RA; Sirota L; Berkower I; Golding H; Weiss CD
    J Infect Dis; 2007 Oct; 196(7):1026-32. PubMed ID: 17763325
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vaccination of BALB/c mice with Escherichia coli-expressed vaccinia virus proteins A27L, B5R, and D8L protects mice from lethal vaccinia virus challenge.
    Berhanu A; Wilson RL; Kirkwood-Watts DL; King DS; Warren TK; Lund SA; Brown LL; Krupkin AK; Vandermay E; Weimers W; Honeychurch KM; Grosenbach DW; Jones KF; Hruby DE
    J Virol; 2008 Apr; 82(7):3517-29. PubMed ID: 18199639
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vaccinia virus H3L envelope protein is a major target of neutralizing antibodies in humans and elicits protection against lethal challenge in mice.
    Davies DH; McCausland MM; Valdez C; Huynh D; Hernandez JE; Mu Y; Hirst S; Villarreal L; Felgner PL; Crotty S
    J Virol; 2005 Sep; 79(18):11724-33. PubMed ID: 16140750
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Smallpox DNA vaccine delivered by novel skin electroporation device protects mice against intranasal poxvirus challenge.
    Hooper JW; Golden JW; Ferro AM; King AD
    Vaccine; 2007 Feb; 25(10):1814-23. PubMed ID: 17240007
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential antigen requirements for protection against systemic and intranasal vaccinia virus challenges in mice.
    Kaufman DR; Goudsmit J; Holterman L; Ewald BA; Denholtz M; Devoy C; Giri A; Grandpre LE; Heraud JM; Franchini G; Seaman MS; Havenga MJ; Barouch DH
    J Virol; 2008 Jul; 82(14):6829-37. PubMed ID: 18448519
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Systemically administered DNA and fowlpox recombinants expressing four vaccinia virus genes although immunogenic do not protect mice against the highly pathogenic IHD-J vaccinia strain.
    Bissa M; Pacchioni SM; Zanotto C; De Giuli Morghen C; Illiano E; Granucci F; Zanoni I; Broggi A; Radaelli A
    Virus Res; 2013 Dec; 178(2):374-82. PubMed ID: 24050999
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mucosal immunization induces a higher level of lasting neutralizing antibody response in mice by a replication-competent smallpox vaccine: vaccinia Tiantan strain.
    Lu B; Yu W; Huang X; Wang H; Liu L; Chen Z
    J Biomed Biotechnol; 2011; 2011():970424. PubMed ID: 21765641
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunization with Varicella-zoster virus glycoprotein E expressing vectors: Comparison of antibody response to DNA vaccine and recombinant vaccinia virus.
    Stasíková J; Kutinová L; Smahel M; Nĕmecková S
    Acta Virol; 2003; 47(1):1-10. PubMed ID: 12828337
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A protein-based smallpox vaccine protects mice from vaccinia and ectromelia virus challenges when given as a prime and single boost.
    Xiao Y; Aldaz-Carroll L; Ortiz AM; Whitbeck JC; Alexander E; Lou H; Davis HL; Braciale TJ; Eisenberg RJ; Cohen GH; Isaacs SN
    Vaccine; 2007 Jan; 25(7):1214-24. PubMed ID: 17098336
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of the deletion of genes encoding proteins of the extracellular virion form of vaccinia virus on vaccine immunogenicity and protective effectiveness in the mouse model.
    Meseda CA; Campbell J; Kumar A; Garcia AD; Merchlinsky M; Weir JP
    PLoS One; 2013; 8(6):e67984. PubMed ID: 23785523
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhanced immunogenicity and protective effect conferred by vaccination with combinations of modified vaccinia virus Ankara and licensed smallpox vaccine Dryvax in a mouse model.
    Meseda CA; Garcia AD; Kumar A; Mayer AE; Manischewitz J; King LR; Golding H; Merchlinsky M; Weir JP
    Virology; 2005 Sep; 339(2):164-75. PubMed ID: 15993917
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential efficacy of vaccinia virus envelope proteins administered by DNA immunisation in protection of BALB/c mice from a lethal intranasal poxvirus challenge.
    Pulford DJ; Gates A; Bridge SH; Robinson JH; Ulaeto D
    Vaccine; 2004 Sep; 22(25-26):3358-66. PubMed ID: 15308360
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The 1.51-Angstrom structure of the poxvirus L1 protein, a target of potent neutralizing antibodies.
    Su HP; Garman SC; Allison TJ; Fogg C; Moss B; Garboczi DN
    Proc Natl Acad Sci U S A; 2005 Mar; 102(12):4240-5. PubMed ID: 15761054
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Parainfluenza virus 5-based vaccine vectors expressing vaccinia virus (VACV) antigens provide long-term protection in mice from lethal intranasal VACV challenge.
    Clark KM; Johnson JB; Kock ND; Mizel SB; Parks GD
    Virology; 2011 Oct; 419(2):97-106. PubMed ID: 21885079
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of a needle-free delivery platform for prime-boost immunization with DNA and modified vaccinia virus ankara vectors expressing herpes simplex virus 2 glycoprotein D.
    Meseda CA; Stout RR; Weir JP
    Viral Immunol; 2006; 19(2):250-9. PubMed ID: 16817767
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Protective immunity to vaccinia virus induced by vaccination with multiple recombinant outer membrane proteins of intracellular and extracellular virions.
    Fogg C; Lustig S; Whitbeck JC; Eisenberg RJ; Cohen GH; Moss B
    J Virol; 2004 Oct; 78(19):10230-7. PubMed ID: 15367588
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.